Lunai Bioworks (LNAI) Liabilities and Shareholders Equity (2011 - 2026)

Lunai Bioworks' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $9.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 91.62% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $31.7 million (down 93.83% YoY), while the FY2025 annual figure was $8.2 million, down 94.95% from the prior year.
• Liabilities and Shareholders Equity was $9.9 million for Q1 2026 at Lunai Bioworks, up from $6.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $180.1 million in Q1 2022 to a low of $6.7 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $82.6 million across 5 years, with a median of $80.3 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity soared 179.81% in 2024, then slumped 94.95% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $80.3 million in 2022, then retreated by 27.72% to $58.0 million in 2023, then jumped by 91.91% to $111.3 million in 2024, then tumbled by 94.01% to $6.7 million in 2025, then soared by 47.91% to $9.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $9.9 million (Q1 2026), $6.7 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.